JP2009539353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539353A5 JP2009539353A5 JP2009513483A JP2009513483A JP2009539353A5 JP 2009539353 A5 JP2009539353 A5 JP 2009539353A5 JP 2009513483 A JP2009513483 A JP 2009513483A JP 2009513483 A JP2009513483 A JP 2009513483A JP 2009539353 A5 JP2009539353 A5 JP 2009539353A5
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- antigen
- clade
- consensus
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 125000002796 nucleotidyl group Chemical group 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108091035707 Consensus sequence Proteins 0.000 claims 1
- 101710177291 Gag polyprotein Proteins 0.000 claims 1
- 102100034353 Integrase Human genes 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- 101710192141 Protein Nef Proteins 0.000 claims 1
- 108010078428 env Gene Products Proteins 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 108010089520 pol Gene Products Proteins 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
Claims (8)
- ＨＩＶ−１クレイドＡのＧａｇ、Ｐｏｌ（ＲＴ及びＩｎｔ）及びＮｅｆ（「ＧＲＩＮ）、ＨＩＶ−１クレイドＡのＧａｇ、ＲＴ及びＮｅｆ（「ＧＲＮ」）、又はＨＩＶ−１クレイドＡのＥｎｖをコードするヌクレオチドを含む、ＨＩＶ−１クレイドＡ抗原用のコンセンサスヌクレオチド。
- コードされるＧａｇタンパク質が配列番号２に示されるアミノ酸配列を有する、請求項１に記載のコンセンサスヌクレオチド。
- コードされるＰｏｌタンパク質が配列番号３に示されるアミノ酸配列を有する、請求項１に記載のコンセンサスヌクレオチド。
- コードされるＥｎｖタンパク質が配列番号４に示されるアミノ酸配列を有する、請求項１に記載のコンセンサスヌクレオチド。
- コードされるＮｅｆタンパク質が配列番号５に示されるアミノ酸配列を有する、請求項１に記載のコンセンサスヌクレオチド。
- ＨＩＶ−１クレイドＡ抗原用コンセンサスアミノ酸配列に類似したアミノ酸配列を有するＨＩＶ−１の流行株又は野外分離株から、ＨＩＶ−１クレイドＡ抗原を同定する方法であって、ＨＩＶ−１の流行株又は野外分離株由来の抗原のアミノ酸配列を当該タンパク質用のコンセンサスアミノ酸配列と比較すること、及びＨＩＶ−１の流行株又は野外分離株から、前記コンセンサス配列とのタンパク質距離が近い抗原を選択することを含む方法。
- トランスジェニックＨＩＶ−１クレイドＡ抗原を産生する方法であって、請求項６に記載の方法により同定されたＨＩＶ−１クレイドＡ抗原を選択すること、及び前記抗原の機能を無効にするように、前記抗原をコードするヌクレオチド配列を変異させることを含む方法。
- 請求項１〜５のいずれかに記載のヌクレオチド又は該ヌクレオチドがコードするタンパク質抗原を含む、ＨＩＶ−１に対して免疫応答を生成するための組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81081606P | 2006-06-02 | 2006-06-02 | |
| PCT/US2007/070321 WO2007143606A2 (en) | 2006-06-02 | 2007-06-04 | Hiv-1 clade a consensus sequences, antigens, and transgenes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009539353A JP2009539353A (ja) | 2009-11-19 |
| JP2009539353A5 true JP2009539353A5 (ja) | 2011-07-28 |
Family
ID=38802278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009513483A Withdrawn JP2009539353A (ja) | 2006-06-02 | 2007-06-04 | Ｈｉｖ−１クレイドａのコンセンサス配列、抗原及びトランス遺伝子 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8119144B2 (ja) |
| EP (2) | EP2399602B1 (ja) |
| JP (1) | JP2009539353A (ja) |
| AU (1) | AU2007256717B2 (ja) |
| CA (1) | CA2654324A1 (ja) |
| DK (2) | DK2399602T3 (ja) |
| ES (2) | ES2528951T3 (ja) |
| WO (1) | WO2007143606A2 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7050310B2 (ja) | 2012-09-19 | 2022-04-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｂ型肝炎ウイルスコアタンパク質および表面抗原タンパク質をコードする核酸分子ならびにそれを含むワクチン |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220061285A (ko) * | 2013-11-14 | 2022-05-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | HIV-1 EnV DNA 백신과 단백질 부스터 |
| KR20220047277A (ko) | 2019-07-16 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
| US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
| US6277558B1 (en) | 1990-11-30 | 2001-08-21 | Kansas University Medical Center | α-3 chain type IV collagen polynucleotides |
| US5650398A (en) | 1992-07-02 | 1997-07-22 | Cambridge Biotech Corporation | Drug delivery enhancement via modified saponins |
| CZ293770B6 (cs) | 1994-12-24 | 2004-07-14 | Cambridge University Technical Services Limited | Farmaceutický prostředek |
| US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
| US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
| US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
| US20020136722A1 (en) | 1997-06-18 | 2002-09-26 | Heath Andrew William | Vaccination method |
| EP1009429B1 (en) | 1997-08-29 | 2009-07-08 | Antigenics Inc. | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| ES2341429T3 (es) * | 1999-12-23 | 2010-06-21 | Medical Research Council | Mejoras en las respuestas inmunitarias al vih o relacionadas con las mismas. |
| CA2412050C (en) | 2000-06-15 | 2011-03-22 | Jeffrey Schlom | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| IT1318103B1 (it) | 2000-07-03 | 2003-07-23 | Nuovo Pignone Spa | Sistema di connessione tra un ugello di bassa pressione ed untransition duct in una turbina a gas |
| KR20070028291A (ko) * | 2003-09-17 | 2007-03-12 | 듀크 유니버시티 | 컨센서스／원형 면역원 |
| WO2005047483A2 (en) * | 2003-11-12 | 2005-05-26 | Medical Research Council | Renta: an hiv immunogen and uses thereof |
-
2007
- 2007-06-04 WO PCT/US2007/070321 patent/WO2007143606A2/en active Application Filing
- 2007-06-04 JP JP2009513483A patent/JP2009539353A/ja not_active Withdrawn
- 2007-06-04 EP EP11005764.3A patent/EP2399602B1/en not_active Not-in-force
- 2007-06-04 ES ES11005764.3T patent/ES2528951T3/es active Active
- 2007-06-04 DK DK11005764.3T patent/DK2399602T3/en active
- 2007-06-04 AU AU2007256717A patent/AU2007256717B2/en not_active Ceased
- 2007-06-04 CA CA002654324A patent/CA2654324A1/en not_active Abandoned
- 2007-06-04 US US11/757,550 patent/US8119144B2/en active Active
- 2007-06-04 DK DK07798067.0T patent/DK2029168T3/da active
- 2007-06-04 EP EP07798067A patent/EP2029168B1/en not_active Not-in-force
- 2007-06-04 ES ES07798067T patent/ES2396915T3/es active Active
-
2012
- 2012-02-17 US US13/398,897 patent/US8735542B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7050310B2 (ja) | 2012-09-19 | 2022-04-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｂ型肝炎ウイルスコアタンパク質および表面抗原タンパク質をコードする核酸分子ならびにそれを含むワクチン |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7250878B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| Medhekar et al. | Diversity-generating retroelements | |
| Mulligan et al. | Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types | |
| Marston et al. | Comparative analysis of the full genome sequence of European bat lyssavirus type 1 and type 2 with other lyssaviruses and evidence for a conserved transcription termination and polyadenylation motif in the G–L 3′ non-translated region | |
| Rong et al. | Unique mutational patterns in the envelope α2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1 | |
| JP2017528158A5 (ja) | ||
| JP2019525914A5 (ja) | ||
| JP2011087580A5 (ja) | ||
| JP2011097941A5 (ja) | ||
| Xiang et al. | Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies | |
| Malherbe et al. | Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits | |
| JP2015529678A5 (ja) | ||
| Fenimore et al. | Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage | |
| Patel et al. | Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins | |
| JP2019522626A5 (ja) | ||
| JP2009539353A5 (ja) | ||
| Alizadeh et al. | Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach | |
| JP2010532656A5 (ja) | ||
| Louz et al. | Animal models in virus research: their utility and limitations | |
| Wang et al. | Codon usage bias in the H gene of canine distemper virus | |
| CN101531719B (zh) | 一种禽流感基因工程多肽抗原 | |
| Azim et al. | Combination of highly antigenic nucleoproteins to inaugurate a cross-reactive next generation vaccine candidate against Arenaviridae family | |
| Shen et al. | Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence | |
| Carrillo | Foot and mouth disease virus genome | |
| JP2008501328A5 (ja) |